Suggested remit: To appraise the clinical and cost effectiveness of ranibizumab port delivery system within its marketing authorisation for treating wet age-related macular degeneration.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process TA
ID number 3983

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
26 December 2022 As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of the Port Delivery System with ranibizumab for treating wet age-related macular degeneration. Please note that following on from advice received from the company the timelines for this appraisal are to be confirmed. The appraisal will be rescheduled to align with latest regulatory expectations and an update on the revised timelines will be provided when further information is available.
14 September 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
01 July 2022 As you will be aware, the Department for Health & Social Care has asked NICE to conduct an appraisal of Ranibizumab port delivery system for treating wet age-related macular degeneration. Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early October 2022. These timings are based on a request from the company to reschedule the initial date set by NICE.
31 May 2022 The topic was discussed at the Topic Selection Oversight Panel (TSOP) in April 2022. The panel concluded that the topic was suitable for a Technology Appraisal. Following conversations with the company, the scheduling of the evaluation is to be confirmed and stakeholders will be updated in due course.
31 May 2022 Topic selection. The topic was discussed at the Topic Selection Oversight Panel (TSOP) in April 2022. The panel concluded that the topic was suitable for a Technology Appraisal. Following conversations with the company, the scheduling of the evaluation is to be confirmed and stakeholders will be updated in due course.
26 January 2022 - 23 February 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
26 January 2022 In progress. In progress
26 January 2022 In progress. .

For further information on our processes and methods, please see our CHTE processes and methods manual